open_UMR

Aaron Beller

A background image with floating blue debris and more debris flowing helix-like in the background

Welcome to open_UMR!

Open_UMR is a cross faculty publication hub. We collect scientific publications, resources, research data and software from members of Philipps-University Marburg and make it openly accessible. To ensure high standards of quality and re-usability, submissions to open_UMR are subject to curation.

Select a community to browse its collections.

Recent Submissions

Open Access
The Talmud Yerushalmi’s Civil Law in Its Ancient Legal Context : Rabbinic Law – Roman Law – Hellenistic Law
(Harrassowitz, 2026)
Hezser, Catherine
;
Willems, Constantin
The Talmud Yerushalmi’s Civil Law in Its Ancient Legal Context provides a historical and comparative examination of legal issues that were shared by both rabbis and jurists during the Roman-Byzantine period. The topics covered concern slaves and manumission, women and property, house building and ownership rights, the treatment of laborers, liability for wild animals, and the broader issue of surveillance and accountability of citizens in the Roman world. The chapters are written by historians of Roman law as well as scholars of rabbinic literature and ancient Judaism. They reveal the shared interest of rabbis and jurists in specific legal issues, their attention to the same details, similarities in legal solutions, and interesting differences that point to social, cultural, and religious concerns. The interdisciplinary volume exemplifies how the inclusion of rabbinic legal traditions in the study of ancient legal systems enables a better understanding not only of Jewish law but also of Roman legal culture and social practice in late antiquity.
Open Access
Arbeitsmigration in der Bundesrepublik : Zeithistorische Perspektiven
(Campus Verlag, 2026)
Mecking, Sabine
;
Rudloff, Wilfried
;
Zloch, Stephanie
In den meisten europäischen Ländern wird heute intensiv um die Deutung und Ausgestaltung der Einwanderungsgesellschaft gerungen. Mit der Perspektive auf individuelle, gesellschaftliche, erinnerungskulturelle und regionalspezifische Zeitschichten und Zeitverläufe von Migration eröffnet dieser Band neue Einsichten über etablierte Zuordnungs- und Bewertungsmuster hinaus. Im Zentrum steht die Arbeitsmigration in die Bundesrepublik, die als eigenes Phänomen »mittlerer Dauer« von den 1950er bis in die 1990er Jahre eine präzise Charakterisierung erfährt. Der Band vereint Beiträge aus der historischen Migrationsforschung, der Zeit-, Regional- und Bildungsgeschichte sowie der Public History und verknüpft damit bislang oftmals getrennte Forschungs- und Diskussionsstränge miteinander.
Open Access
Living Forest Constitutionalism : Indigenous Jurisprudence and Rights of Nature in the Ecuadorian Amazon
(transcript Verlag, 2026)
García Ruales, Jenny
If Pacha Mama or Nature was already recognised as a subject of rights in Ecuador’s Constitution, why did the Kichwa People of Sarayaku declare their territory the Living Forest (Kawsak Sacha) in 2018 – ›a living and conscious being with rights of its own‹? Drawing on accompanied legal ethnography in the Ecuadorian Amazon, Jenny García Ruales traces this question through Indigenous jurisprudence and the more-than-human normativities of the Living Forest. She develops Living Forest Constitutionalism, a constitutional theory that reimagines the foundations of constitutionalism from the jurisprudence of the Living Forest. An essential resource for scholars and readers seeking to rethink where constitutions come from, who makes law, and what it means to defend life.
Open Access
Klinische und laborchemische Charakterisierung von Patientinnen und Patienten mit Morbus Crohn unter Biologika-Therapie als Grundlage für spektrale durchflusszytometriebasierte immunologische Clusteranalysen
(2026-09-28)
Dittrich, Jehona
;
Bauer, Christian
;
Bekeredjian-Ding, Isabelle
Background: Crohn’s disease shows heterogeneous activity at the clinical, systemic, and mucosal level. In the sense of a treat-to-target approach, this work uses a triad consisting of the Crohn’s Disease Activity Index, C-reactive protein, and fecal calprotectin to characterize remission quality and discordances under biologic therapy. An internal project discussion status on peripheral immune profiling using spectral flow cytometry is additionally included as background for group formation, without reporting immunological analyses as results in this disserta- tion. Methods: In a monocentric cross-sectional analysis, four cohorts were examined: active disease (n = 11), remission under infliximab, an antibody against tumor necrosis factor (n = 15), under ustekinumab, an antibody against interleukin 12 and 23 (n = 12), and under risankizumab, an antagonist against interleukin 23 (n = 8). Triad thresholds were defined as fecal calprotectin of at most 100 milligrams per kilogram, C-reactive protein of at most 5 milligrams per liter, and the Crohn’s Disease Activity Index of at most 150. The analysis was purely descriptive, based on individual values and proportions below thresholds; predefined out- liers were clinically contextualized. Results: The active disease cohort showed low triad target attainment (fecal calpro- tectin/C-reactive protein/Crohn’s Disease Activity Index: 18%/27%/9%). In all remission cohorts, the Crohn’s Disease Activity Index threshold was achieved in 100%, with variable systemic and mucosal quiescence: infliximab 60%/80%/100%, ustekinumab 33%/50%/100%, and risankizumab 38%/50%/100% (fecal calprotectin/C-reactive protein/Crohn’s Disease Activity Index). Thus, fecal calprotectin proved to be a demanding marker of residual mucosal activity. Outliers could be plausibly explained clinically by segmental, perianal, or stenosing manifestations as well as exposure differences. Conclusion: A conservatively defined triad consisting of the Crohn’s Disease Activity Index, C-reactive protein, and fecal calprotectin allows a differentiated characterization of patients with Crohn’s disease under biologic therapy and makes clinical- laboratory discordances visible. The results support a treat-to-target strategy in which clinical goals are consistently complemented by biomarkers. For further research, prospective studies with synchronized measurement time points and tissue-based validation appear meaningful.
Open Access
Dosimetric assessment of [68Ga]Ga-PSMA-11 PET/CT towards increasing the clinical impact in the management of patients with advanced prostate cancer
(2026-09-14)
Bagheri, Shamim
;
Luster, Markus
;
Adeberg, Sebastian
Introduction: Prostate‑specific membrane antigen (PSMA) has emerged as a highly specific molecular target for both diagnostic imaging and radioligand therapy in metastatic castration‑resistant prostate cancer (mCRPC). Reliable quantification of radiotracer kinetics is essential for personalized dosimetry, particularly for [177Lu]Lu‑PSMA‑617 radioligand therapy. However, conventional multi‑time‑point imaging protocols are resource‑intensive and difficult to implement in routine clinical practice. This thesis therefore, pursued a combined preclinical and clinical strategy in which the preclinical findings were used to design, optimize, and justify a simplified clinical dosimetry workflow based on segmentation, reconstruction, and pharmacokinetic modelling. Methods: The preclinical part employed dynamic PET and static SPECT/CT imaging in murine and chorioallantoic membrane (CAM) models to systematically evaluate segmentation strategies, reconstruction parameters, and kinetic modelling frameworks. Gradient‑based and threshold‑based volumes of interest (VOIs) methods were compared, and reconstruction stability was assessed across ordered‑subsets expectation‑maximization (OSEM) parameter variations. Dynamic murine PET data enabled the derivation of arterial input functions, parent‑fraction curves, and multi‑tissue time–activity curves, supporting one‑ and two‑tissue compartment modelling. The insights gained from these preclinical experiments, particularly regarding segmentation robustness, reconstruction stability, and the suitability of the two‑tissue compartment model, were directly translated into the clinical workflow. The clinical part included 35 mCRPC patients undergoing [177Lu]Lu‑PSMA‑617 radioligand therapy. Planar and/or SPECT/CT imaging was performed at 24 h and 48 h post‑injection. A total of 259 organ‑specific time–activity curves (across kidneys, salivary glands, liver) were generated using population‑based pharmacokinetic (PBPK) modelling. Validation was performed in 20 patients with multi‑time‑point reference dosimetry (2–196 h). Baseline [68Ga]Ga‑PSMA‑11 PET/CT was used to derive voxel‑based pre‑therapy dose coefficients. Accuracy was assessed using relative deviations, root mean square error (RMSE), mean absolute error (MAE), Bland–Altman analysis, and linear regression. Results: Preclinical investigations demonstrated that gradient‑based segmentation provided superior boundary conformity and reproducibility, particularly in the CAM model. Reconstruction analysis identified a parameter window in which standardized uptake value stability and VOI reproducibility were maintained. Kinetic modelling showed that the two‑tissue compartment model yielded physiologically meaningful fits, supported by high‑quality arterial input functions and parent‑fraction corrections. These preclinical findings formed the methodological foundation for the clinical PBPK workflow, ensuring that segmentation, reconstruction, and modelling choices were evidence‑based and optimized prior to clinical application. Clinically, the two‑time‑point PBPK approach produced time integrated activities (TIAs) and absorbed doses closely matching multi‑time‑point reference dosimetry. Median relative deviations were about 12%, and RMSEs ranged from 6.2% to 12.4% across organs. Pre‑therapy [68Ga]Ga‑PSMA‑11 PET/CT dose coefficients correlated strongly with first‑cycle absorbed doses (R2 = 0.74–0.89). Bland–Altman analyses showed minimal bias (<0.1 Gy/GBq) and clinically acceptable limits of agreement, with over 90% of estimates within ± 20% of reference values. Conclusion: This thesis demonstrates that a simplified two‑time‑point PBPK dosimetry workflow, informed and optimized by preclinical segmentation, reconstruction, and kinetic modelling studies, provides reliable and reproducible time integrated activities and absorbed doses for [177Lu]Lu‑PSMA‑617 radioligand therapy. The workflow achieves accuracy comparable to multi‑time‑point protocols while substantially reducing imaging burden. Pre‑therapy [68Ga]Ga‑PSMA‑11 PET/CT further enables reliable prediction of first‑cycle organ doses. Together, these findings establish a validated, scalable workflow that supports routine personalized dosimetry in PSMA‑targeted radioligand therapy.